Replacement of cellular with acellular pertussis (aP) vaccines has considerably reduced the
systemic reactions observed with diphtheria-tetanus toxoids-pertussis vaccine but has not …

Effective diphtheria, tetanus toxoids, whole-cell pertussis (DTwP) vaccines became
available in the 1930s, and they were put into routine use in the United States in the 1940s …

This review was stimulated in part by three articles that presented a view of acellular
pertussis vaccine development," which we believe is not supported by the clinical and …

Bordetella pertussis 165-9K/129G, which produces a nontoxic form of pertussis toxin (PT),
was used to prepare a whole-cell diphtheria-tetanus-pertussis (DTP) vaccine. The in vivo …

A double-blind, randomized, controlled trial comparing 4 lots of acellular pertussis-
diphtheria tetanus toxoids vaccine (APDT) to whole cell DTP vaccine in 397 children was …

Available data relating to pertussis and pertussis immunization are frequently overlooked or
misinterpreted. Mortality due to pertussis is underreported. Most whole cell pertussis …

The safety and immunogenicity of an acellular pertussis vaccine containing the genetically
detoxified pertussis toxin PT-9K/129C, filamentous hemagglutinin, and pertactin, together …

A critical level of serum IgG pertussis toxin antibody is both essential and sufficient to confer
individual and herd immunity to pertussis. Monocomponent pertussis toxoid conferred such …

Two clinical studies were undertaken to evaluate the immunogenicity of an adult-type dTpa
booster vaccine (Boostrix™ by GlaxoSmithKline Biologicals). Blood samples taken prior to …

Diphtheria-tetanus-acellular pertussis vaccines have been licensed in the United States
since 1991. Compared with the whole cell pertussis component diphtheria-tetanus-pertussis …